Aug 08, 2026 — Digital Edition
Gerald Ideas
Independent Journalism & Insight
Feature

RNA m6a Methylation Regulator Expression in Castration Resistant exquisite roundup

RNA m6a Methylation Regulator Expression in Castration

RNA m6a Methylation Regulator Expression in Castration Resistant
RNA m6a Methylation Regulator Expression in Castration Resistant

Using mass spectrometry and RNA sequencing, this study profiles the dynamic m6A regulator expression patterns in prostate cancer. It identifies specific regulators whose expression significantly changes during cancer development, therapy resistance, and progression to advanced stages like castration-resistant prostate cancer.

Downregulation of CAMK2N1 due to DNA Hypermethylation Mediated by DNMT1
Downregulation of CAMK2N1 due to DNA Hypermethylation Mediated by DNMT1

N6-methyladenosine ( m6A ) methylation , a prevalent epitranscriptomic modification, plays a crucial role in regulating mRNA expression , stability, and translation in mammals. M6A regulators have gained attention for their potential implications in tumorigenesis and clinical applications, such as cancer diagnosis and therapeutics. The existing literature predominantly addresses m6A regulators in ...

RNA m6a Methylation Regulator Expression in Castration

Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression

The existing literature predominantly addresses m6A regulators in the context of primary prostate cancer (PCa). However, a notable gap in the knowledge emerges regarding the dynamic expression patterns of these regulators as PCa progresses towards the castration-resistant stage (CRPC).

Abstract N6-methyladenosine ( m6A ) methylation , a prevalent epitranscriptomic modification, plays a crucial role in regulating mRNA expression , stability, and translation in mammals. M6A regulators have gained attention for their potential implications in tumorigenesis and clinical applications, such as cancer diagnosis and therapeutics.

Stages of Prostate Cancer
Stages of Prostate Cancer

RNA m6a Methylation Regulator Expression in Castration

The existing literature predominantly addresses m6A regulators in the context of primary prostate cancer (PCa). However, a notable gap in the knowledge emerges regarding the dynamic expression patterns of these regulators as PCa progresses towards the castration-resistant stage (CRPC).

Liyanage, Chamikara, Fernando, Achala, Chamberlain, Audrey, Moradi, Afshin, Batra, Jyotsna (2024) RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic Associations. Cancers, 16 (7), pp.Article number: 1303. 1 citations on Web of Science 1 citations on ScopusView on ePrintsRNA m6a Methylation Regulator Expression in Castration-Resistant ...

Prostate Cancer Progression and the Epigenome
Prostate Cancer Progression and the Epigenome

RNA m6a Methylation Regulator Expression in Castration

Liyanage C, Fernando A, Chamberlain A, Moradi A, Batra J. RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic Associations.

N6-methyladenosine ( m6A ) methylation , a prevalent epitranscriptomic modification, plays a crucial role in regulating mRNA expression , stability, and translation in mammals. M6A regulators have gained attention for their potential implications in tumorigenesis and clinical applications, such as cancer diagnosis and therapeutics.

Prostate Cancer Signaling Pathway
Prostate Cancer Signaling Pathway

Key Details About Rna M6A Methylation Regulator Expression In Castration Resistant

In this study, we analyzed the characteristic expression of m 6 A regulators in PCa and castration-resistant prostate cancer (CRPC). UALCAN and cBioPortal were used to estimate the clinical value and genetic alterations of m 6 A regulators , respectively.

Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression
Prostate cancer immunotherapy Improving clinical outcomes with a multi
Prostate cancer immunotherapy Improving clinical outcomes with a multi
downregulation of septin5 inhibits prostate cancer progression by
downregulation of septin5 inhibits prostate cancer progression by
Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression
Frontiers
Frontiers
PDF Cytomegalovirus infection is common in prostate cancer
PDF Cytomegalovirus infection is common in prostate cancer
Stages of Prostate Cancer The Focal Therapy Clinic
Stages of Prostate Cancer The Focal Therapy Clinic

In conclusion, METTL3 activated the ERK pathway and induced the resistance to Enzalutamide by regulating the m6A level of critical gene transcription in the ERK pathway.